Dupilumab for recalcitrant prurigo nodularis: Case report
Portuguese Journal of Dermatology and Venereology（2022）
摘要
Dupilumab is a recombinant fully human monoclonal antibody modulating the signaling of the interleukin (IL)—4 and IL-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. We present a case of recalcitrant prurigo nodularis treated off-label with dupilumab.
更多查看译文
关键词
Antibodies. Monoclonal. Humanized. Dupilumab. Prurigo/drug therapy.
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要